Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific Inc (NYSE:TMO), reported the sale of $2,059,261 in company common stock on March 5, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The transactions were carried out at prices between $503.66 and $519.74 per share.
In the same filing Casper disclosed that he exercised stock options to acquire 4,000 shares at an exercise price of $309.63, representing a total outlay of $1,238,520. The share sales were executed pursuant to a Rule 10b5-1 trading plan that Casper adopted on November 11, 2025.
After completing these moves, Casper's direct ownership stands at 124,705.358 shares of Thermo Fisher common stock. The filing also lists indirect holdings: 11,300 shares held through the Alison Casper 2020 Irrevocable Trust, 14,608 shares via Floral Park Associates, Inc., and 5,000 shares through the MNC 2020 Irrevocable Trust.
Market context and valuation notes
The life sciences equipment company has a reported market capitalization of $189.5 billion. The stock has traded near $510 and, despite that trading level, has declined by roughly 12% year-to-date.
An InvestingPro analysis included with the filing indicates the shares currently appear overvalued relative to the service's Fair Value estimate. The analysis also notes that Thermo Fisher has a "GOOD" financial health score and has raised its dividend for eight consecutive years. For subscribers, a Pro Research Report covering TMO and more than 1,400 other U.S. equities is available.
Recent financial performance and cash-return action
Thermo Fisher reported fourth-quarter 2025 results that exceeded consensus expectations. Adjusted earnings per share were $6.57 versus an expected $6.45, and revenue came in at $12.21 billion compared with a forecast of $11.89 billion.
The company also announced a 10% increase in its quarterly cash dividend, raising the payout to $0.47 per share from $0.43. That dividend will be payable on April 15, 2026, to shareholders of record as of March 13, 2026.
Financing for acquisition
To support its pending acquisition of Clario Holdings, Inc., Thermo Fisher has priced a $3.8 billion senior notes offering. The package includes various notes with maturities ranging from 2031 to 2046, according to the filing details included in the company disclosure.
What the filings disclose and what remains unchanged
- Casper's $2,059,261 in stock sales occurred on March 5, 2026, at prices between $503.66 and $519.74.
- He exercised options to buy 4,000 shares at $309.63 for a total of $1,238,520.
- The share sales were made under a Rule 10b5-1 trading plan adopted on November 11, 2025.
- Post-transaction ownership totals include 124,705.358 shares held directly and specified indirect holdings through three trusts and an entity.
The filings and company announcements provide a snapshot of insider activity, recent operating results, shareholder returns, and the financing structure associated with the pending acquisition. They leave a clear record of executed transactions and disclosed holdings without indicating further management plans beyond what is filed.